Cellular Therapy Archive

A building with a stone facade displays a sign that reads
Kaveh Najafi, D.O., F.A.C.S.
A building with a stone facade displays a sign that reads
Courtney E. Mellen, MSN-Ed, AGNP-C, OCN
A building with a stone facade displays a sign that reads
Molly M. Drought, M.S.N., F.N.P.-C.
A building with a stone facade displays a sign that reads
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
A building with a stone facade displays a sign that reads
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A building with a stone facade displays a sign that reads
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
A building with a stone facade displays a sign that reads
A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator’s Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
A building with a stone facade displays a sign that reads
Guidance Document for Compassionate Use (CU) Treatment with glofitamab for patients with relapsed/refractory Diffuse Large b-Cell Lymphoma (r/r DLBCL), transformed follicular Lymphoma (tFL) or Primary Mediastinal B-Cell Lymphoma (PMBCL)